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Abstract 1 
 2 
Aims: Brain-derived neurotrophic factor (BDNF) plays important roles in angiogenesis, 3 
inflammation, and neuronal plasticity. BDNF methylation has been extensively investigated 4 
in depression, but not in cardiac diseases. We asked whether BDNF methylation status is 5 
associated with a major adverse cardiac event (MACE), inflammation, and the association 6 
with depression comorbidity and its treatment in patients with acute coronary syndrome 7 
(ACS). 8 
Methods and results: A cross-sectional baseline study and nested 24 week double-blind 9 
escitalopram placebo-controlled trial (ClinicalTrial.gov identifier NCT00419471) were 10 
performed from 2006 to 2012, with 5–12 year follow-up for MACE. Patients with recent 11 
ACS (969 total) were divided into four groups according to depression comorbidity at 12 
baseline and treatment allocation: 591, absent depression; 127, depression on escitalopram; 13 
128, depression on placebo; 123, depression on care as usual (CAU). BDNF methylation was 14 
measured in leucocyte DNA, and multiple demographic and clinical characteristics including 15 
interleukin 6 were evaluated as covariates at baseline. The primary outcome, time to first 16 
MACE (a composite of all-cause mortality, myocardial infarction and percutaneous coronary 17 
intervention), was investigated using Cox regression models after adjustment for covariates. 18 
Interleukin 6 level was significantly higher in patients with higher BDNF methylation values. 19 
Higher BDNF methylation was associated with increased MACE independent of confounding 20 
factors [HR (95% CI) = 1.45 (1.17-1.78)]. This association was significant in patients without 21 
depression [HR (95% CI) = 1.39 (1.01-1.90)] and depressive patients on placebo [HR (95% 22 
CI) = 1.72 (1.02-3.02)] or CAU [HR (95% CI) = 1.53 (1.01-2.61)], but not in those treated 23 
with escitalopram [HR (95% CI) = 1.00 (0.51-1.95)]. 24 
Conclusion: BDNF methylation was significantly associated with prognosis of ACS. 25 
 3 
Escitalopram may mitigate the deleterious effect of higher BDNF methylation in depressive 1 
patients with ACS. Further research is needed to elucidate the mechanistics and to assess the 2 
generalisability of these findings. 3 
Clinical Trial: ClinicalTrial.gov registry number for 24week trial: NCT00419471 4 
Keywords: acute coronary syndrome; epigenetic methylation; BDNF; depression; cohort 5 
study 6 
 7 
Abbreviations: BDNF, brain-derived neurotrophic factor; MACE, major adverse cardiac 8 
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 4 
Introduction 1 
 2 
Acute coronary syndrome (ACS) is the leading cause of mortality and disability worldwide 3 
(GBD 2016 DALYs and HALE Collaborators, 2017). Multiple biochemical markers are 4 
involved in the prognosis of ACS (Panteghini, 2004). Recently, several lines of evidence have 5 
indicated that epigenetic factors play key roles in the development of atherosclerosis, the 6 
main underlying mechanism of ACS (Grimaldi et al., 2015). ‘Epigenetics’ refers collectively 7 
to alterations in gene expression not associated with changes in sequence or responses to 8 
environmental stimuli (Bernstein et al., 2007). DNA methylation, one of the most well-known 9 
epigenetic modifications, entails covalent methylation of the C5 position of cytosine residues 10 
followed by guanine residues (CpG dinucleotides) (Wolffe et al., 1999). 11 
Most previous studies of the association between DNA methylation status in 12 
candidate genes and ACS employed a case-control design. Hypermethylation in the 13 
promoters of ESR1 (oestrogen receptor 1) (Huica et al., 2011), ABCG1 (ATP-binding cassette 14 
subfamily G member 1) (Peng et al., 2014) and FOXP3 (forkhead box P3) (Jia et al., 2013), 15 
and hypomethylation in the promoter of IL6 (interleukin 6) (Yang et al.,2016), are associated 16 
with ACS. A few studies have investigated this issue in a high-risk population of patients with 17 
ACS from the standpoint of risk of recurrence or death. The results revealed that 18 
hypomethylation of F2RL3 (F2R-like thrombin or trypsin receptor 3) is associated with 19 
increased mortality in ACS patients (Breitling et al., 2012). 20 
Epigenetic modification of the gene encoding brain-derived neurotrophic factor 21 
(BDNF) has been implicated in ACS. BDNF enhances vascular flow and promotes 22 
revascularisation of ischemic tissue (Donovan et al., 2000; Kermani et al., 2005). Notably in 23 
this context, higher serum BDNF is associated with decreased risk of CVD and mortality 24 
(Kaess et al., 2015). BDNF expression is regulated by an epigenetic mechanism; i.e., 25 
 5 
hypermethylation of the BDNF promoter is associated with reduced synthesis of BDNF 1 
(Martinowich et al., 2003). Therefore, BDNF hypermethylation may be associated with poor 2 
prognosis of ACS by increasing morbidity or mortality. 3 
BDNF hypermethylation has also been associated with elevated risk of depressive 4 
disorder (Fuchikami et al., 2011; Kim et al., 2013) and better response to antidepressant 5 
treatment (Tadić et al., 2014; Kim et al., 2015a), both in general and ACS populations. In 6 
addition, comorbidity and treatment of depression have affected cardiac outcomes in patients 7 
with ACS (Lespérance et al., 2002; Kim et al., 2018a). These observations beg the question of 8 
whether depression may have a role on the association between BDNF methylation status and 9 
prognosis of ACS. 10 
We previously reported that higher BDNF methylation status was independently 11 
associated with depressive disorder in 969 patients with recent ACS (Kim et al., 2015b). By 12 
extending the cohort and to address these unanswered questions, we sought to investigate 13 
whether BDNF methylation status affects the long-term prognosis of ACS and examine 14 
whether these effects differed according to depression comorbidity and treatment status.15 
 6 
Methods  1 
 2 
Study outline and participants 3 
The analyses described in this study were carried out using data from a prospective 4 
observational study of patients with ACS, Korean DEPression in ACS (K-DEPACS), which 5 
also included a nested randomised clinical trial (RCT) for patients with depression and ACS, 6 
Escitalopram for DEPression in ACS (EsDEPACS). The design and main findings of K-7 
DEPACS and EsDEPACS have been published (Kim et al., 2018a; Kim et al., 2018b), and the 8 
eligibility criteria are described in the online supplementary material. This investigation 9 
conformed to the principles outlined in the Declaration of Helsinki. Written informed consent 10 
was collected for both studies, which were approved by the Chonnam National University 11 
Hospital (CNUH) Institutional Review Board. The outline and participant recruitment 12 
process for analysis performed in this study are presented in Figure 1. 13 
 14 
K-DEPACS baseline evaluation 15 
From 2006 to 2012, participants were consecutively recruited from patients recently 16 
hospitalised with ACS at the Department of Cardiology, CNUH, Gwangju, South Korea. This 17 
department was nominated by the Korean Circulation Society to serve as the central 18 
coordinating centre for the Korea Acute Myocardial Infarction Registry (KAMIR) (Lee et al., 19 
2011). KAMIR is a nationwide prospective, multicenter, online registry 20 
(http://kamir5.kamir.or.kr/) designed as a surveillance platform to track clinical outcomes of 21 
patients with acute MI without exclusion criteria to reflect real-world practice; this enables 22 
prospective associations to be evaluated for a range of exposures or interventions with long-23 
term cardiac outcomes. Patients were treated by cardiologists participating in the study based 24 
on international guidelines for the management of ACS (Anderson et al., 2012). Those who 25 
 7 
met eligibility criteria and agreed to participate were selected for K-DEPACS. All baseline 1 
evaluations, including depression, were made in a hospital within 2 weeks of the ACS 2 
episode. Diagnoses of depressive disorder were determined by psychiatrists using the Mini-3 
International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998), a structured 4 
diagnostic psychiatric interview for disorders in the Diagnostic and Statistical Manual of 5 
Mental Disorders, Fourth Edition (DSM-IV) (American Psychiatric Association, 1994), 6 
defining major or minor depressive disorder categories as outputs. According to these criteria, 7 
patients were diagnosed as having major depressive disorder if they had at least one core 8 
symptom (i.e., depressed mood or loss of interest) and at least four other symptoms of 9 
depression, and as having minor depressive disorder if they had at least one core symptom 10 
and at least two but fewer than five total symptoms. 11 
BDNF methylation status was examined in patients who agreed to offer blood 12 
samples. DNA was extracted from venous blood using standard procedures. The BDNF 13 
region chosen for methylation analysis is a CpG-rich area (containing nine CpG sites) in exon 14 
VI that also serves as the promoter region; it is located from nucleotides -612 to -463 relative 15 
to the transcriptional start site in exon VIII (online Figure S1). These data have been 16 
deposited in GenBank (accession number: BankIt1568919 BDNF JX848620). This region 17 
was chosen because it corresponds to an analogous region of rat BDNF that is differentially 18 
methylated and associated with BDNF mRNA expression and because it has been 19 
investigated in the context of antenatal depression (Roth et al., 2009; Devlin et al., 2010). 20 
Genomic DNA (1 µg) was extracted from leucocytes using the QIAamp DNA Blood 21 
Mini Kit (Qiagen, Valencia, CA, USA). The DNA was then subjected to bisulphite treatment 22 
using the EpiTech Bisulfite Kit (Qiagen). A 150 bp fragment of the BDNF promoter was 23 
amplified by polymerase chain reaction (PCR) from bisulphite-treated DNA using the 24 
forward (5’-GTGGGGTAGGAGGGGAGTAGTAT-3’) and reverse (5’-25 
 8 
AAATCCCCCAATCAACTCTCT-3’) primers. PCR conditions were as follows: 95°C for 15 1 
minutes, followed by 45 cycles of 95°C for 15 seconds, 57°C for 30 seconds and 72°C for 15 2 
seconds, with a final extension of 5 minutes at 72°C. PCR products were sequenced using the 3 
PSQ 96M Pyrosequencing System (Biotage) using the primer 5’-4 
GGTAGGAGGGGAGTAGTA-3’. The methylation percentage at each CpG region was 5 
quantified using the Pyro Q-CpG software, version 1.0.9 (Biotage). Individual methylation 6 
percentages at the remaining six CpG sites and their average values were used in the analyses. 7 
Because the methylation percentage at CpG sites 2, 6 and 8 was 100% in all participants, 8 
these three sites were excluded.  9 
Information was collected regarding characteristics that could potentially affect 10 
cardiac outcomes (Jaffe et al., 2006). Demographic data were obtained on age, gender, 11 
education, marital status, living alone, housing and employment status. For depression 12 
characteristics, the self-completed Beck Depression Inventory (BDI) (Beck et al., 1961) score 13 
and previous or family history of depression were recorded. The following cardiovascular 14 
risk factors were ascertained: diagnosed hypertension and diabetes mellitus, 15 
hypercholesterolemia by fasting serum total cholesterol level (>200 mg/dL), obesity (based 16 
on measured body mass index), reported current smoking status, and previous and family 17 
histories of ACS. Cardiac severity status was identified: ACS diagnosis (MI or unstable 18 
angina), Killip classification (Killip et al., 1967), left ventricular ejection fraction and serum 19 
levels of troponin I and creatine kinase-MB. Since pro-inflammatory cytokines reduced the 20 
BDNF gene expression (Lapchak et al., 1993), serum IL6 level was also measured. 21 
 22 
The nested EsDEPACS study 23 
Of patients with baseline diagnoses of depressive disorder, those who met eligibility criteria 24 
and agreed to participate were randomised into a 24 week, double-blind, placebo-controlled 25 
 9 
trial of escitalopram, the EsDEPACS study (ClinicalTrial.gov registry number: 1 
NCT00419471). The first patient was enrolled in May 2007, and the last patient completed 2 
follow-up evaluation in March 2013. Examinations were scheduled at baseline, and in weeks 3 
4, 8, 12, 16, 20 and 24 thereafter. The primary efficacy measure was the Hamilton Depression 4 
Rating Scale (HAMD) (Hamilton et al., 1960). The details and main results of this trial have 5 
been published previously (Kim et al., 2015a): escitalopram was superior to placebo in both 6 
primary depressive and secondary outcomes. The remaining participants who did not meet 7 
the eligibility criteria or declined participation in the trial received conventional medical 8 
treatment for ACS only.  9 
 10 
Long-term cardiac outcomes 11 
Comprehensive evaluations for cardiac outcomes are possible for this study because KAMIR 12 
manages and records detailed electronic data on hospital admissions, deaths, recurrent 13 
myocardial infarction (MI) and percutaneous coronary intervention (PCI). All baseline 14 
participants were successfully followed up for these outcomes. To enable non-hierarchic 15 
endpoint analyses, all patients were followed for the evaluation point of interest or until death. 16 
The primary endpoint was a major adverse cardiac event (MACE), which was a composite of 17 
all-cause mortality, MI and PCI. Secondary endpoints were all-cause mortality, cardiac death 18 
(defined as sudden death when no other explanation was available, death from arrhythmias or 19 
after MI or heart failure, or death caused by heart surgery or endocarditis), MI and PCI. An 20 
independent endpoint committee composed of study cardiologists adjudicated all potential 21 
events and was blinded to the participants’ depression comorbidity. 22 
 23 
Statistical analyses 24 
According to their depression comorbidity and treatment status at baseline, the patients were 25 
 10 
divided into four groups: absent depression, depression on escitalopram, depression on 1 
placebo and depression on care as usual (CAU). Baseline demographic and clinical 2 
characteristics were compared between the four groups by analysis of variance or χ2 tests 3 
with post-hoc comparisons. BDNF methylation percentages were categorised by a binary 4 
variable with value ‘lower’ or ‘higher’ (i.e., below or above median value), arbitrarily but in 5 
keeping with previous research (Breitling et al., 2012). Baseline characteristics were 6 
compared again between patients with lower and higher average BDNF methylation values 7 
using t-tests or χ2 tests, as appropriate. Characteristics significantly associated with average 8 
BDNF methylation values (p<0.05) and other variables with potential effects on MACE were 9 
used as covariates in further adjusted analyses. Kaplan–Meier models were used to compare 10 
the cumulative proportion of participants experiencing composite and individual MACE 11 
(defined according to the date of the first event for each patient) between those with lower 12 
and higher BDNF methylation values. Cox proportional hazards models were used to 13 
compare time to first composite and individual MACE, after adjustment for the potential 14 
covariates described above, between the two groups. To investigate the extent of mediating 15 
effects of baseline characteristics cluster on the associations between average BDNF 16 
methylation values and MACE outcomes, Cox proportional hazards models were repeated by 17 
adjusting the characteristics cluster on socio-demographics, depression, cardiac risk factors, 18 
and current cardiac status, separately. To evaluate the differences in effects of average BDNF 19 
methylation values on composite and individual MACE, the Cox proportional hazards models 20 
were used in these four groups with calculating interaction terms after adjustment for all the 21 
potential covariates. Additional sensitivity analyses were conducted using the methylation 22 
value as a continuous exposure variable (10 percent unit increase) to reexamine its effect 23 
beyond the binary categorical approach. All statistical tests were two-sided with a 24 
significance level of 0.05. Statistical analyses were carried out using the SPSS 21.0 and 25 
 11 
STATA 12.0 software.1 
 12 
Results  1 
 2 
Recruitment 3 
The recruitment process is described in Figure 1. Of 4809 patients with ACS, 1152 were 4 
recruited, of whom 969 (84%) agreed to provide blood samples. Those who did or did not 5 
agree to provide blood samples did not differ significantly with respect to any baseline 6 
characteristic (all p-values >0.15). Of these 969 participants, depressive disorder at baseline 7 
was absent in 591 and present in 378 (39%). Of those with depressive disorder, 255 8 
participated in the EsDEPACS trial (127 randomised to escitalopram and 128 to placebo), and 9 
123 received CAU. Baseline characteristics are described for these four groups in online 10 
Table S1. Significant group differences were found in gender, marital status, living alone, 11 
housing, employment status, BDI scores, DSM-IV diagnosis of depressive disorder, 12 
hypertension, diabetes, smoking status, and ACS diagnosis. In particular, the two treatment 13 
allocated groups had more severe depression pathologies than the CAU group. All 14 
participants were followed for cardiac outcomes over 5–12 years, until 2017 or their death 15 
[median; mean (standard deviation) duration of follow-up = 8.4; 8.7 (1.5) years]. 16 
 17 
BDNF methylation status and baseline characteristics 18 
Median (interquartile rage) and mean (standard deviation) percentages of average BDNF 19 
methylation and methylation at six individual CpG sites are described in online Table S2. The 20 
methylation percentages of the six CpG sites were highly correlated (online Table S3). Given 21 
these high correlations, the results of the following analyses were robust for average CpG 22 
values and similar but less obvious for individual CpG sites. Therefore, we only present the 23 
results for average CpG values in the main manuscript; those for individual CpG values are 24 
reported in the online supplementary material. In Table 1, baseline characteristics are 25 
 13 
compared between subjects with lower and higher average BDNF methylation values. A 1 
higher average BDNF methylation value was significantly associated with unmarried marital 2 
status, unemployment, higher BDI scores, depression comorbidity and treatment, family 3 
history of depression and, lower LVEF., and higher serum IL-6 levels. These characteristics 4 
were included as covariates in subsequent analyses (except for depression comorbidity and 5 
treatment, to avoid collinearity with BDI scores). In addition, age, education, all cardiac risk 6 
factors and current cardiac status variables were also considered as covariates because they 7 
have been associated with cardiac outcomes in previous studies (Panteghini. et al., 2004; 8 
Jaffe et al., 2006).  9 
 10 
Effects of average BDNF methylation values on the occurrence of MACE 11 
The primary endpoint (composite MACE) occurred in 383 participants (39.5%), and 12 
secondary endpoints occurred in 178 (18.4%) for all-cause mortality, 98 (10.1%) for cardiac 13 
death, 101 (10.4%) for MI and 139 (14.3%) for PCI. Figure 2 illustrates cumulative risk of 14 
the composite MACE in subjects with lower and higher average BDNF methylation. A 15 
significant difference was observed: composite MACE incidences were 33.1% (159/481) in 16 
lower and 45.9% (224/488) in higher [hazard ratio (HR), 1.45 (95% CI, 1.17–1.78); p-17 
value=0.001]. Figure 3 illustrates cumulative risks of individual MACE components in the 18 
two groups. Significant differences were observed in the incidences of all-cause mortality 19 
[15.0% in lower and 21.7% in higher (HR, 1.40 [95% CI, 1.03–1.91]; p-value=0.033)] and 20 
PCI [12.1% in lower and 16.6% in higher (HR, 1.45 [95% CI, 1.03–2.05]; p-value=0.035)]. 21 
However, the groups did not differ significantly in the incidence of cardiac death and MI. 22 
Effects of a higher average BDNF methylation at baseline on MACE outcomes after 23 
adjustment for baseline characteristics cluster are summarised in online Table S4. 24 
Considering the crude associations (1st row), the effect of BDNF methylation on MACE was 25 
 14 
substantially reduced by depression characteristics (Model 3) but not by other characteristics 1 
(Models 2, 4, and 5). 2 
 3 
Effects according to depression comorbidity and treatment 4 
Baseline BDNF methylation average percentages were significantly higher in patients with 5 
depressive disorder (mean, 39.5–39.6) than in those without (mean, 36.9) (p-value<0.001), 6 
but similar among the three groups of depressive patients (p-value=0.990). Incidences of the 7 
composite MACE were 31.5% (186/591) in patients without depression, 42.5% (54/127) in 8 
depressive patients on escitalopram, 54.7% (70/128) in depressive patients on placebo and 9 
59.3% (73/123) in depressive patients on CAU. Significant differences were found between 10 
patients with and without depression (p-value<0.001), and among patients with depression 11 
(p-value=0.022). Effects of average BDNF methylation values on the incidences of MACE 12 
according to depression comorbidity and treatment status are summarised in Table 2. In 13 
patients without depression, a higher average BDNF methylation value was significantly 14 
associated with the incidences of composite MACE, all-cause mortality and cardiac death. In 15 
depressive patients on placebo, a higher average BDNF methylation value was significantly 16 
associated with the incidences of composite MACE and MI. In depressive patients on CAU, a 17 
higher average BDNF methylation value was significantly associated with the incidences of 18 
composite MACE and all-cause mortality. However in depressive patients on escitalopram, 19 
BDNF methylation average status was not associated with any MACE outcomes. The BDNF 20 
methylation x depressive status multiplicative interaction terms were statistically significant 21 
only for the cardiac death outcome. Results on additional sensitivity analysis using the 22 
methylation percentages as a continuous variable are summarized in the online Table S5. The 23 
strengths of the associations were not substantially changed. 24 
 25 
 15 
Effects of individual BDNF methylation values on the occurrence of MACE 1 
Effects of BDNF methylation individual values on the occurrence of MACE are summarised 2 
in online Tables S6–S10. Higher BDNF methylation percentages at CpG3, CpG7 and CpG9 3 
were significantly associated with the incidence of composite MACE; a higher BDNF 4 
methylation percentage at CpG9 was significantly associated with the incidence of all-cause 5 
mortality; and a higher BDNF methylation percentage at CpG3 was significantly associated 6 
with the incidences of MI and PCI.7 
 16 
Discussion 1 
 2 
The principal finding from this cohort study was that higher BDNF methylation status 3 
measured at acute phase was significantly associated with worse long-term prognosis of ACS, 4 
independent of potential confounding factors. This association was significant in patients 5 
without depression, as well as in depressive patients on placebo or CAU, but not in 6 
depressive patients treated with escitalopram. 7 
Several mechanisms might explain the significant association between higher BDNF 8 
methylation and worse prognosis of ACS. In animals, BDNF is an endothelial cell survival 9 
factor that plays an essential role in stabilising intramyocardial vessels by stimulating 10 
angiogenesis, regulating vascular flow and promoting the revascularisation of ischemic tissue 11 
(Donovan et al., 2000; Kermani et al., 2005). In humans, lower blood BDNF levels are 12 
associated with higher risk and worse prognosis of cardiovascular disease (Kaess et al., 2015; 13 
Manni et al., 2005; Fukushima et al., 2015). Given that BDNF release is reduced in 14 
individuals with higher methylation percentages (Martinowich et al., 2003), restorative 15 
angiogenic actions against ischemic injury may be impaired in such patients, thereby 16 
increasing the risks of recurrence and death. Although our findings have not been reported 17 
previously in ACS, similar results were reported in a post-stroke cohort, in which a higher 18 
BDNF promoter methylation status was independently associated with 1 year stroke 19 
functional outcomes, specifically, worsening of physical disability and cognitive function 20 
(Kim et al., 2012). In addition, this result supports the existing literature on the epigenetic 21 
effects of other genes on the risk or prognosis of ACS (Huica et al., 2011; Peng et al., 2014; 22 
Jia et al., 2013; Yang et al., 2016; Breitling et al., 2012).  23 
The BDNF methylation sites investigated in this present study are associated with 24 
depressive disorder in the general population (Devlin et al., 2010) and in physical disorders 25 
 17 
including ACS (Kim et al., 2015b) and stroke (Kim et al., 2013). There is ample evidence that 1 
comorbid depression is associated with poor outcomes of ACS, including increased mortality 2 
and nonfatal events (Lespérance et al., 2002). Moreover, the effect of BDNF methylation on 3 
MACE was substantially reduced by depression characteristics rather than other socio-4 
demographic or cardiac characteristics (see online Table S4). Therefore, it is reasonable to 5 
hypothesise that the associations between BDNF methylation and ACS prognosis may be 6 
influenced by depression status. However, the association remained significant after 7 
adjustment for depression severity (baseline BDI scores). Furthermore, the association was 8 
significant not only in patients without depression, but also in depressive patients on placebo 9 
and CAU, although the methylation percentages were significantly higher in patients with 10 
depression than in those without. In addition, pro-inflammatory cytokines have influenced 11 
both ACS and depression (Lespérance et al., 2004), and its effects were mediated by BDNF 12 
(Calabrese et al., 2014) The BDNF methylation value was significantly associated with serum 13 
IL6 levels (see Table 1), but its effect on ACS prognosis was independent of IL6 levels. 14 
BDNF methylation status was also associated with unmarried marital and unemployed status, 15 
and a family history of depression at baseline, which could be considered as other evidence of 16 
epigenetic changes. However, these characteristics had little influence on the associations 17 
between BDNF methylation and MACE outcomes. These observations imply that the effect 18 
of BDNF methylation status on prognosis of ACS is related to angiogenic activity, rather than 19 
being mediated by baseline depression or inflammatory status as well as behavioural or 20 
historical characteristics.  21 
It is noteworthy that BDNF methylation status was not associated with prognosis of 22 
ACS in depressive patients treated with escitalopram. Successful antidepressant treatment 23 
responses are associated with elevated peripheral BDNF levels in patients with major 24 
depressive disorder (Sen et al., 2008; Molendijk et al., 2011). One possible mechanism for the 25 
 18 
association observed in this study is phosphorylation of methyl-CpG-binding protein 2 1 
(MeCP2), which acts as an repressor of gene expression, followed by dissociation of MeCP2 2 
from DNA (Hutchinson et al., 2012). Because BDNF methylation is a prerequisite for specific 3 
MeCP2 binding, it is possible that escitalopram dissociated MeCP2 from DNA and increased 4 
the expression of BDNF, thereby counteracting the risk of worse cardiac outcomes. However, 5 
we cannot confirm these assumptions because BDNF methylation was not re-assayed at 6 
follow-up. In the sample randomised into the EsDEPACS trial, escitalopram was more 7 
effective at treating depression (Kim et al., 2015a) and associated with better cardiac 8 
outcomes than placebo (Kim et al., 2018b). Therefore, it is also possible that successful 9 
depression treatment with escitalopram may promote better health behaviour, such as 10 
increased hospital engagement and treatment adherence (Smolderen et al., 2017), which are 11 
closely related to ACS prognosis. 12 
Average BDNF methylation percentages were the primary values analysed in this 13 
study, and this approach has been repeatedly used in other studies (Lubin et al., 2008; Kelle et 14 
al., 2010). With respect to the individual CpG sites, higher BDNF methylation percentages at 15 
CpG3, CpG7 and CpG9 predicted worse prognosis of ACS. Because these associations were 16 
weaker than the association with average values, future replications are needed to confirm 17 
these findings. 18 
As the first evaluation of these questions, this study has several strengths, and also 19 
benefits from a unique prospective observational and randomised placebo-controlled 20 
interventional study design. Participants were recruited at baseline consecutively from among 21 
all eligible patients with a recent ACS, thereby decreasing the risk of error arising from 22 
heterogeneous examination times and increasing the sample homogeneity. Depressive 23 
disorder was ascertained using a structured diagnostic interview, and all measurement 24 
methods for psychiatric and cardiovascular characteristics were well validated. Multiple 25 
 19 
covariates were considered in the analyses. Recruitment was carried out at a single site, 1 
potentially limiting the generalisability of the present findings, but representing an advantage 2 
in terms of consistency of evaluation and treatment of patients. One important limitation of 3 
this study is that we investigated methylation status in only one CpG island in the BDNF gene, 4 
although this area has been repeatedly evaluated in previous epigenetic research on 5 
depression (Fuchikami et al., 2011; Roth et al., 2009; Devlin et al., 2010; Kang et al., 2015). 6 
Another source of limitation was attrition in the recruitment process: methylation analysis 7 
was only possible in 84% of the baseline sample. However, baseline demographic and 8 
clinical characteristics did not differ between patients for which this information was or was 9 
not available. Moreover, long-term follow-up data on MACE are completely obtained for the 10 
primary analysis. The study hypotheses were based on prior studies, but the study results 11 
could not provide mechanistic evidences, which need future studies. Finally, those taking 12 
antidepressants or having a history of neuropsychiatric illnesses were excluded for the 13 
EsDEPACS trial, which may represent less severe depression pathologies in these treatment 14 
groups and therefore limit the generalizability. However, scores on BDI were significantly 15 
higher in EsDEPACS allocated group compared to the CAU group (online Table S1). 16 
In conclusion, higher BDNF methylation status at acute phase of ACS was associated 17 
with worse long-term prognosis, independent of potential confounders and irrespective of 18 
baseline depressive status. BDNF methylation tests might have clinical utility in screening for 19 
epigenetic susceptibility to identify at-risk groups for recurrence or ACS-related mortality; 20 
therefore, this status represents a promising prognostic biomarker in these patients. 21 
Escitalopram reduced the negative effect of higher BDNF methylation on ACS prognosis. 22 
Future studies with other antidepressants, or in non-depressive subjects, could elucidate the 23 
exact mechanism. Our results suggest that drugs capable of regulating BDNF methylation, 24 
should they be developed, could improve prognosis of ACS.  25 
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Figure 1. Flow diagram for the recruitment process. 1 
 2 
Figure legends: 3 
ACS: acute coronary syndrome; BDI: Beck Depression Inventory; MINI: Mini-International 4 
Neuropsychiatric Interview. K-DEPACS: Korean DEPression in Acute Coronary Syndrome; 5 
EsDEPACS: Escitalopram for DEPression in Acute Coronary Syndrome. 6 
 7 
 8 
9 
 30 
Figure 2. Cumulative incidence (%) of composite major adverse cardiac event (MACE), by 1 
average BDNF methylation at baseline. 2 
 3 
Figure legends: 4 
Hazard ratio (95% confidence interval) [HR (95% CI)] was estimated adjusted for age, 5 
education, marital status, employment, Beck Depression Inventory scores, family history of 6 
depression, hypertension, diabetes, hypercholesterolemia, obesity, smoking, previous and 7 
family history of acute coronary syndrome (ACS), ACS diagnosis, Killip class, left 8 
ventricular ejection fraction, and serum levels of troponin I, creatine kinase-MB, and 9 
interleukin-6 at baseline. 10 
 11 
 12 
13 
 31 
Figure 3. Cumulative incidence (%) of individual major adverse cardiac event (MACE), by 1 
average BDNF methylation at baseline. 2 
 3 
Figure legends: 4 
Hazard ratio (95% confidence interval) [HR (95% CI)] was estimated adjusted for age, 5 
education, marital status, employment, Beck Depression Inventory scores, family history of 6 
depression, hypertension, diabetes, hypercholesterolemia, obesity, smoking, previous and 7 
family history of acute coronary syndrome (ACS), ACS diagnosis, Killip class, left 8 
ventricular ejection fraction, and serum levels of troponin I, creatine kinase-MB, and 9 
interleukin-6 at baseline. 10 
 11 
 12 
  13 
 32 
Table 1. Baseline characteristics by average BDNF methylation 2 weeks after acute coronary 
syndrome (ACS). 
 Lower 
methylation 
(N=481) 
Higher 
methylation 
(N=488) 
Statistical 
coefficient 
P-value* 
Socio-demographic characteristics    
Age, mean (SD) years 58.1 (11.1) 58.3 (11.2) t=-0.331 0.741 
Gender, N (%) female 125 (26.0) 144 (29.5) χ2=1.497 0.221 
Education, mean (SD) years 10.0 (4.6) 9.7 (4.7) t=+1.048 0.295 
Unmarried marital status, N (%) 59 (12.3) 82 (16.8) χ2=4.011 0.045 
Living alone, N (%) 45 (9.4) 47 (9.6) χ2=0.021 0.884 
Housing, N (%) rented 70 (14.6) 80 (16.4) χ2=0.627 0.428 
Currently unemployed, N (%) 162 (33.7) 206 (42.2) χ2=7.489 0.006 
Depression characteristics, N (%)    
BDI, mean (SD) score 8.6 (8.1) 11.4 (8.9) t=-5.213 <0.001 
Depression comorbidity and treatment    
No depression 341 (70.9) 250 (51.2) χ2=39.59 <0.001 
Depression on escitalopram 48 (10.0) 79 (16.2)   
Depression on placebo 48 (10.0) 80 (16.4)   
Depression on care as usual 44 (9.1) 79 (16.2)   
Previous depression 16 (3.3) 18 (3.7) χ2=0.094 0.759 
Family history of depression 6 (1.2) 17 (3.5) χ2=5.227 0.022 
Cardiac risk factors, N (%)     
Hypertension 235 (48.9) 223 (45.7) χ2=0.970 0.325 
Diabetes mellitus 89 (18.5) 102 (20.9) χ2=0.881 0.348 
 33 
Hypercholesterolemia 233 (48.4) 253 (51.8) χ2=1.122 0.289 
Obesity 210 (43.7) 255 (42.0) χ2=0.270 0.604 
Current smoker 191 (39.7) 175 (35.9) χ2=1.526 0.217 
Previous ACS 18 (3.7) 21 (4.3) χ2=0.197 0.657 
Family history of ACS 16 (3.3) 15 (3.1) χ2=0.050 0.823 
Current cardiac status     
ACS diagnosis, N (%)     
Myocardial infarction 351 (73.0) 363 (74.4) χ2=0.249 0.618 
Unstable angina 130 (27.0) 125 (25.6)   
Killip class >1, N (%) 92 (19.1) 76 (15.6) χ2=2.134 0.144 
LVEF, mean (SD) % 62.0 (11.2) 60.4 (11.4) t=+2.204 0.027 
Troponin I, mean (SD) mg/dL 9.8 (14.5) 10.0 (15.3) t=-0.193 0.847 
CK-MB, mean (SD) mg/dL 17.8 (35.5) 17.0 (38.9) t=+0.343 0.732 
Interleukin-6, mean (SD) pg/mL 23.9 (17.1) 27.2 (19.9) t=-2.255 0.024 
*p-values using t-tests or χ2 tests as appropriate.  
BDI, Beck Depression Inventory; LVEF, left ventricular ejection fraction; and CK-MB, Creatine 
kinase-MB. 
 34 
Table 2. Associations of a higher average BDNF methylation at baseline with long-term cardiac outcomes in patients with acute coronary 
syndrome (ACS), by depression comorbidity and randomised treatment status. Data are hazard ratios (95% confidence intervals) [HRs (95% 
CIs)]. 
 Absent depression 
(N=591) 
Depression on 
escitalopram 
(N=127) 
Depression on 
placebo (N=128) 
Depression on care 
as usual (N=123) 
P-value for 
interaction 
Major adverse cardiac events 1.39 (1.01-1.90)* 1.00 (0.51-1.95) 1.72 (1.02-3.02)* 1.53 (1.01-2.61)* 0.591 
All-cause mortality 1.72 (1.08-2.70)† 0.86 (0.36-2.07) 1.47 (0.45-4.77) 1.89 (1.00-3.99)* 0.624 
Cardiac death 2.20 (1.01-4.20)* 0.24 (0.05-1.11) 1.02 (0.50-2.91) 1.94 (0.53-7.11) 0.012 
Myocardial infarction 0.88 (0.48-1.62) 6.83 (0.28-67.38) 3.43 (1.00-12.35)* 1.17 (0.34-3.99) 0.103 
Percutaneous coronary intervention 1.33 (0.81-2.18) 0.76 (0.22-2.67) 1.39 (0.53-3.62) 1.37 (0.53-3.53) 0.882 
HR (95% CI) was estimated adjusted for age, education, marital status, employment, Beck Depression Inventory scores, family history of 
depression, hypertension, diabetes, hypercholesterolemia, obesity, smoking, previous and family history of ACS, ACS diagnosis, Killip class, 
left ventricular ejection fraction, and serum levels of troponin I, creatine kinase-MB, and interleukin-6 at baseline. 
*p-value<0.05; † p-value<0.01. 
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